Chemomab Therapeutics Ltd. (CMMB)
NASDAQ: CMMB · Real-Time Price · USD
1.810
-0.060 (-3.21%)
At close: Jan 6, 2026, 4:00 PM EST
1.840
+0.030 (1.66%)
After-hours: Jan 6, 2026, 6:07 PM EST
Chemomab Therapeutics Employees
Chemomab Therapeutics had 20 employees as of December 31, 2021.
Employees
20
Change
n/a
Growth
n/a
Revenue / Employee
n/a
Profits / Employee
-$504,250
Market Cap
11.14M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2021 | 20 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
CMMB News
- 5 weeks ago - Chemomab Therapeutics Announces Nebokitug Phase 2 SPRING Trial Results in Primary Sclerosing Cholangitis Published in the American Journal of Gastroenterology - GlobeNewsWire
- 6 weeks ago - Chemomab to Participate in Oppenheimer's Movers in Rare Disease Summit - GlobeNewsWire
- 6 weeks ago - Chemomab Therapeutics Announces Third Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewsWire
- 2 months ago - Chemomab Announces Multiple Presentations at AASLD The Liver Meeting® 2025 Featuring Clinical Data from the Nebokitug Phase 2 Trial in Primary Sclerosing Cholangitis - GlobeNewsWire
- 4 months ago - Chemomab Therapeutics to Present at H.C. Wainwright 27th Annual Global Investment Conference - GlobeNewsWire
- 5 months ago - Chemomab Therapeutics Announces Second Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewsWire
- 6 months ago - Chemomab Announces Oral Presentation of Positive Nebokitug Phase 2 Clinical Data in Primary Sclerosing Cholangitis at BSG Live'25 - GlobeNewsWire
- 7 months ago - Chemomab Reports Positive Feedback From Two Recent FDA Meetings Supporting Phase 3 Advancement of Nebokitug in Primary Sclerosing Cholangitis - GlobeNewsWire